Wilson Sonsini Goodrich & Rosati·PHARMA / BIOTECH
MFN Drug Pricing EO reshapes cross-border life sciences deal drafting
A law-firm client alert traces Executive Order 14297's most-favored-nation pricing mandate to its consequences for pricing, exclusivity and supply terms in cross-border life sciences transactions.
most-favored-nationdrug-pricingexecutive-order-14297life-sciences-m-and-across-border-dealspharma-commercial-terms
Read the original firm alert → Tuesday, October 20, 2026